Loading clinical trials...

Phase II Study of RR110 in Patients With Active Crohn's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Phase II Study of RR110 in Patients With Active Crohn's Disease

NCT00417391•R&R Inc.

Summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with CDAI score ranging from 220 to 450
•Patients with CRP \> 1 mg/dL
•Patients who can be hospitalized at least 2 weeks after first administration

Exclusion Criteria

•Patients who have previously used anti-TNF antibody, cyclosporine, methotrexate or tacrolimus within 12 weeks of screening
•Patients who have had surgical bowel resections within 4 weeks of screening
•Patients who have previously used total parental nutrition or more than 900 kcal/day of enteral nutrition within 4 weeks of screening

Locations (8)

Toyohashi, Aichi-ken, Japan

Sakura, Chiba, Japan

Sapporo, Hokkaido, Japan

Nishinomiya, Hyōgo, Japan

Fujisawa, Kanagawa, Japan

Nakagami, Okinawa, Japan

Ōtsu, Shiga, Japan

Shinjuku, Tokyo, Japan

Key Dates

Start Date

December 1, 2006

Primary Completion Date

May 1, 2008

Completion Date

May 1, 2008

Last Updated

May 29, 2008

Enrollment

ESTIMATED participants

Conditions

Crohn's Disease

Interventions

RR110 (Tamibarotene)

DRUG

RR110 (Tamibarotene)

DRUG

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGPHASE3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931

Crohn's Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 29, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase II Study of RR110 in Patients With Active Crohn's Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease